CAR-T Congress EU 2019 | Kisaco Research
Discovery, Translation, Commercialisation: Developing CAR-T into viable, accessible therapies
London, United Kingdom
30-31 January, 2019
Download Agenda
The Audience
Register

Why Attend

CAR-T cell therapy has shown unparalleled success in haematological malignancies, paving the way for the field of immuno-oncology. In 2017 two therapies achieved FDA approval in the USA, and following recent approval by the EMA, it is a landmark time for the industry.

Despite the huge successes there are still a number of hurdles to overcome before CAR-T can be effective in mainstream oncology beyond haematological malignancies. The European CAR-T Congress’ mission is to address the opportunities and challenges that presently face the CAR-T field, to maximise the potential of this ground-breaking therapy.

Sessions include:

  • Solid tumour targeting: overcoming the tumour microenvironment
  • Multi-specific & dual targeting CARs
  • Process development, scalability & automation
  • Allogeneic vs Autologous: the potential of off-the-shelf therapies
  • Patient access, implementation & regulatory challenges
  • Advances in gene engineering
  • Safety and toxicity

2018 IMAGE GALLERY

CAR-T image gallery

TESTIMONIALS

CAR-T EU testimonials

WHO WILL BE THERE

Network with industry experts from:

  • Big pharma and biotech
  • Cell Therapy Academics and clinicians 
  • Process standardisation - technology/services
  • Logistics companies - cell storage/transport
  • Service providers - CRO’s, Consultants, Government

Past attendees include:

CAR-T EU Logo Cloud

The Agenda

Simply fill in this form and we'll send you a PDF version of the agenda immediately. We need some information to know where to send the file and how to address our email to you.

CAR-T EU front cover

Check out the highlights from the CAR-T Congress USA earlier this year: 

Download agenda

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

The Speakers

 

Michael Kalos

Vice President
Janssen

Michael Kalos is a graduate of the University of Minnesota Medical School, where he received his PhD from the department of Microbiology with an emphasis in Genetics. He completed postdoctoral fellowships at the Fred Hutchinson Cancer Research Center where he played an early role in the development of genetic approaches to redirect lymphocyte specificity. 
In 1997 Dr. Kalos joined Corixa Corporation, where he engaged in the pre-clinical immunological evaluation of novel cancer vaccines for prostate and lung cancer.

Michael Kalos

Vice President
Janssen

Michael Kalos is a graduate of the University of Minnesota Medical School, where he received his PhD from the department of Microbiology with an emphasis in Genetics. He completed postdoctoral fellowships at the Fred Hutchinson Cancer Research Center where he played an early role in the development of genetic approaches to redirect lymphocyte specificity. 
In 1997 Dr. Kalos joined Corixa Corporation, where he engaged in the pre-clinical immunological evaluation of novel cancer vaccines for prostate and lung cancer.


In 2004 Dr. Kalos was recruited to City of Hope where he established a GLP-level laboratory focused on the development of biomarker strategies to evaluate T cell immunotherapies. 


In 2008 Dr Kalos was recruited to the University of Pennsylvania School of Medicine where he established the Translational and Correlative Studies Laboratory, focused on development and implementation of an integrated biomarker infrastructure as part of the institution's T cell immunotherapy program. Data from his laboratory played an instrumental role in the clinical evaluation and development of the CTL019 program, and has led to a series of high-impact and field-leading publications.

In October 2013 Dr Kalos joined Eli Lilly and company as Chief Scientific Officer for Cancer Immunobiology. At Eli Lilly Dr. Kalos was responsible for establishing and developing a robust and product focused immunotherapy strategy and program.

In March of 2018 Dr. Kalos joined Janssen as Vice President, Immuno-oncology and Oncology Cellular Therapies, where is responsible for developing and leading an integrated Immunotherapy program focused on next-generation and transformative immune therapies.

Dr. Kalos is an internationally recognized expert in T cell immunotherapy. 

 

Dr John Maher

Clinical Senior Lecturer/Honorary Consultant/CSO
King's College London/Leucid Bio

Dr John Maher

Clinical Senior Lecturer/Honorary Consultant/CSO
King's College London/Leucid Bio
 

Tatiana Golovina, PhD

Fellow, Cell & Gene Therapy, Process Development
Novartis Pharmaceuticals Corporation

Tatiana Golovina, PhD

Fellow, Cell & Gene Therapy, Process Development
Novartis Pharmaceuticals Corporation
 

Kip Cross

Director, Customer Engagement
Kite Pharma

Kip Cross

Director, Customer Engagement
Kite Pharma
 

Peggy Sotiropoulou

R&D Manager
Celyad

Peggy Sotiropoulou

R&D Manager
Celyad
 

Dan Ollendorf

Chief Scientific Officer
ICER

Dan Ollendorf

Chief Scientific Officer
ICER
 

Dr. med. Detlev Parow, MBA

Head of Department of Medicines, Therapeutic Appliances and Remedies
Product-and Billing, Management Division, DAK –Gesundheit

Dr. med. Detlev Parow, MBA

Head of Department of Medicines, Therapeutic Appliances and Remedies
Product-and Billing, Management Division, DAK –Gesundheit
 

Dr Giovanna Lombardi

Professor of Human Transplant Immunology in the Division of Transplantation Immunology and Mucosal Biology, MRC Centre for Transplantation
Kings College London

Giovanna Lombardi is Professor of Human Transplant Immunology in the Division of Transplantation Immunology and Mucosal Biology, MRC Centre for Transplantation, at King’s College London (since 2005). From 1987 to 2005 she was based at the Department of Immunology at the Hammersmith Hospital and before that at the University of Rome, Italy.

Dr Giovanna Lombardi

Professor of Human Transplant Immunology in the Division of Transplantation Immunology and Mucosal Biology, MRC Centre for Transplantation
Kings College London

Giovanna Lombardi is Professor of Human Transplant Immunology in the Division of Transplantation Immunology and Mucosal Biology, MRC Centre for Transplantation, at King’s College London (since 2005). From 1987 to 2005 she was based at the Department of Immunology at the Hammersmith Hospital and before that at the University of Rome, Italy.

Her research has focused on the mechanisms of transplant rejection and tolerance as well as on the phenotype and function of regulatory T cells (Tregs) in health and disease, both in the murine system and in man. Recently her laboratory has established a clinical protocol to expand Tregs in vitro. Tregs has been used in two clinical trials in renal transplant patients as part of a large EU cell therapy consortium and in liver transplant patients supported by the MRC. In parallel, her group has demonstrated that adoptive cell therapy using alloantigen-specific regulatory T cells can offer an advantage compared to polyclonal Tregs for preventing chronic allograft rejection. A GMP compatible cell sorter to generate highly pure Tregs is under validation and this approach will open the possibility of using alloantigen-specific Tregs for future clinical trials within the next few years.

 

Dr David Sourdive, PhD

Executive Vice President Technical Operations
Cellectis

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016.

Dr David Sourdive, PhD

Executive Vice President Technical Operations
Cellectis

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.

 

Fiona Thistlethwaite

Christie Foundation, NHS

Fiona Thistlethwaite

Christie Foundation, NHS
 

John Bridgeman

Founder
Immetacyte

John Bridgeman

Founder
Immetacyte
 

Michaela Sharpe, PhD

Head of Clinical Development
Cell and Gene Therapy Catapult

Michaela Sharpe is the Head of Nonclinical Safety and Immunotherapy Strategy at the Cell and Gene Therapy Catapult. Michaela has over fifteen years’ experience in the Pharmaceutical Industry both in the biotechnology sector and large pharma where she has specialised in the nonclinical development of cell based therapies and therapeutic vaccines. She was Head of the Stem Cell Safety Group at Pfizer and prior to joining the Catapult she ran her own consultancy business.

Michaela Sharpe, PhD

Head of Clinical Development
Cell and Gene Therapy Catapult

Michaela Sharpe is the Head of Nonclinical Safety and Immunotherapy Strategy at the Cell and Gene Therapy Catapult. Michaela has over fifteen years’ experience in the Pharmaceutical Industry both in the biotechnology sector and large pharma where she has specialised in the nonclinical development of cell based therapies and therapeutic vaccines. She was Head of the Stem Cell Safety Group at Pfizer and prior to joining the Catapult she ran her own consultancy business. Michaela oversees Immunotherapy Strategy for the Catapult as well as leading a team with significant expertise in the design of non-clinical safety programmes and the development of specialist clinical assays. She has implemented nonclinical development programmes for pluripotent stem cell therapies, somatic cell therapies, immune therapies, genetically modified cell therapies and tissue engineered products.

 

Thierry Wurch

Director, External Research & Innovation in Oncology
Servier

Thierry Wurch

Director, External Research & Innovation in Oncology
Servier
 

Alasdair Rankin

Director of Research & Patient Experience
Bloodwise

Alasdair Rankin is Director of Research and Patient Experience at the blood cancer research charity Bloodwise. In addition to research, his responsibilities include Bloodwise’s policy and campaigning work, and its information and support services for people affected by blood cancer. Previously he was Director of Research at Diabetes UK from 2012 to 2015 where he developed the organisations current research strategy, including leading the establishment of diabetes Clinical Studies Groups and broadening engagement of people living with diabetes in research.

Alasdair Rankin

Director of Research & Patient Experience
Bloodwise

Alasdair Rankin is Director of Research and Patient Experience at the blood cancer research charity Bloodwise. In addition to research, his responsibilities include Bloodwise’s policy and campaigning work, and its information and support services for people affected by blood cancer. Previously he was Director of Research at Diabetes UK from 2012 to 2015 where he developed the organisations current research strategy, including leading the establishment of diabetes Clinical Studies Groups and broadening engagement of people living with diabetes in research. He began working for research funders at Cancer Research UK, where he held various roles including leading the research funding operations team and establishing and leading the research strategy team, contributing to the development and implementation of Cancer Research UK’s 2011-15 research strategy.  Alasdair is an elected Trustee of the National Cancer Research Institute.

 

Luis Álvarez-Vallina

Associate professor, Immunotherapy and Cell Engineering, Department of Engineering
Aarhus University

Luis Álvarez-Vallina attended Medical School at Oviedo University and completed a residency in Immunology at the Clínica Puerta de Hierro (Madrid). Luis earned a PhD in Immunology from the Autónoma University of Madrid and spent four years at the MRC Centre for Protein Engineering (Cambridge, UK). His work contributed to the first generation of CARs with costimulatory domains. Currently, he is Associate Professor at Aarhus University (Denmark) where he leads the Immunotherapy and Cell Engineering group.

Luis Álvarez-Vallina

Associate professor, Immunotherapy and Cell Engineering, Department of Engineering
Aarhus University

Luis Álvarez-Vallina attended Medical School at Oviedo University and completed a residency in Immunology at the Clínica Puerta de Hierro (Madrid). Luis earned a PhD in Immunology from the Autónoma University of Madrid and spent four years at the MRC Centre for Protein Engineering (Cambridge, UK). His work contributed to the first generation of CARs with costimulatory domains. Currently, he is Associate Professor at Aarhus University (Denmark) where he leads the Immunotherapy and Cell Engineering group. He is also heading the Cancer Immunotherapy Unit at Hospital Universitario 12 de Octubre, and Director Immunology Chair Merck- Francisco de Vitoria University (Spain). His experience includes generation of multispecific antibodies, and the development of cancer immunotherapy strategies based on the adoptive transfer of genetically engineered cells secreting bispecific antibodies.

 

Marleen van Loenen

Director Preclinical Development
Gadeta

Marleen van Loenen is Director Preclinical Development at Gadeta, a R&D company that focusses on the development of αβT cells modified with γδ T cell receptors to combat both hematological and solid cancers. Her experience in and enthusiasm for adoptive immunotherapy strategies started with her PhD at Leiden University Medical Center in TCR-gene transfer for hematological malignancies. Subsequently, she moved to Sanquin Amsterdam to study presence and fitness of tumor-reactive TILs within NSCLC, before joining Gadeta in 2017.

Marleen van Loenen

Director Preclinical Development
Gadeta

Marleen van Loenen is Director Preclinical Development at Gadeta, a R&D company that focusses on the development of αβT cells modified with γδ T cell receptors to combat both hematological and solid cancers. Her experience in and enthusiasm for adoptive immunotherapy strategies started with her PhD at Leiden University Medical Center in TCR-gene transfer for hematological malignancies. Subsequently, she moved to Sanquin Amsterdam to study presence and fitness of tumor-reactive TILs within NSCLC, before joining Gadeta in 2017.

 

Michael Hudecek

Hematology/Oncology Division, Medical School of the Julius Maximilians University

Michael Hudecek

Hematology/Oncology Division, Medical School of the Julius Maximilians University
 

Xiaokui Zhang, PhD

hief Scientific Officer
Celularity

Xiaokui Zhang, PhD

hief Scientific Officer
Celularity
 

Dr Zoltan Ivics

Head of Transposition and Genome Engineering
Paul Ehrlich Institute

Dr Zoltan Ivics

Head of Transposition and Genome Engineering
Paul Ehrlich Institute
 

Dr Sarah Snykers

Quality Control Manager
Celyad

Sarah has over 10 years of experience in cell therapy, biomedical research and development.

Dr Sarah Snykers

Quality Control Manager
Celyad

Sarah has over 10 years of experience in cell therapy, biomedical research and development.
She is a pharmacist from education and has a PhD in pharmaceutical and biomedical sciences, specialised in stem cell biology. In 2010, she joined Promethera BioSciences, a biopharmaceutical company dedicated to the development of cell therapy products based on allogeneic adult stem cell technology to treat liver diseases. She headed the R&D, QC and Preclinical Departments. In 2015, she joined Celyad, a biopharmaceutical company, specialised in autologous and allogeneic cell therapy. Celyad’s core business lies in the field of immune-oncology, and more specifically the development of NK-receptor based CAR T therapies. Sarah initially led the immune-oncology program at R&D level, focused on technology transfer, product characterization and optimization. Since 2016, she heads the QC Department.

 

Anna Prokůpková

Policy & Project Officer
European Cancer Leagues

Anna Prokůpková

Policy & Project Officer
European Cancer Leagues
 

Dr Ignacio Anegon

Director of research
INSERM-French Institute of Health and Medical Research, University of Nantes

Dr Ignacio Anegon

Director of research
INSERM-French Institute of Health and Medical Research, University of Nantes
 

Nina (Ekaterini) Kotsopoulou

DPhil | VP, Process Development
Autolus



Nina (Ekaterini) Kotsopoulou

DPhil | VP, Process Development
Autolus



 

Dr Gemma Owens

Clinical Research Fellow and Specialist Registrar
Clinical and Experimental Immunotherapy Group, Division of Cancer Sciences, University of Manchester

Gemma Owens is a clinical research fellow and registrar in obstetrics and gynaecology with a specialist interest in gynaecological cancers. She attended Medical School at Queen’s University (Belfast), and completed an Academic Clinical Fellowship at St Mary’s Hospital, Manchester. She has recently completed a PhD at the University of Manchester, where she worked with Professor Robert Hawkins, Professor Richard Edmondson and Dr David Gilham. Her PhD focused on adoptive immunotherapy strategies for epithelial ovarian cancer, working on both TIL and CAR-T cell approaches.

Dr Gemma Owens

Clinical Research Fellow and Specialist Registrar
Clinical and Experimental Immunotherapy Group, Division of Cancer Sciences, University of Manchester

Gemma Owens is a clinical research fellow and registrar in obstetrics and gynaecology with a specialist interest in gynaecological cancers. She attended Medical School at Queen’s University (Belfast), and completed an Academic Clinical Fellowship at St Mary’s Hospital, Manchester. She has recently completed a PhD at the University of Manchester, where she worked with Professor Robert Hawkins, Professor Richard Edmondson and Dr David Gilham. Her PhD focused on adoptive immunotherapy strategies for epithelial ovarian cancer, working on both TIL and CAR-T cell approaches. In collaboration with Oxford Biomedica, Gemma has demonstrated that 5T4 is an attractive target for CAR-T cell therapy in ovarian cancer.

Poster submission - deadline 14.12.2018

Looking to showcase your recent work to the CAR-T community?

Our dedicated poster session is the perfect way to get your research noticed and further involve yourself in the congress. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration).

At the Congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the afternoon networking break on day one.

Submit your poster abstract here.

Poster abstract submission deadline is on 14th December 2018.

Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!

Resources

Download Resource

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Registration Host

Event Partner

Media Partners

Become a Sponsor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

Saturday, December 1, 2018 to Thursday, January 31, 2019
Academic/Physician Standard Rate
£799 + VAT
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Nathan Edwards, [email protected]
Saturday, December 1, 2018 to Thursday, January 31, 2019
Pharma & Biotech Standard Rate
£1699 + VAT
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Nathan Edwards, [email protected]
Saturday, December 1, 2018 to Thursday, January 31, 2019
Vendors/Service Providers Standard Rate
£1899 + VAT
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Nathan Edwards, [email protected]
Preparing registration...

Book a Team to Save More!

PLEASE NOTE: Team Discounts are only available for Industry Pricing
Book a Team of 3+
 - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

Payment Terms for Combined CAR-T Congress Europe:

  • Please note that a £49 processing fee will apply to any invoices requested.
  • All Prices are in GBP and are exclusive of VAT @ 20%
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined with any other offer.
  • Please view our Cancellation Policy.
  • QUESTIONS? Please email [email protected].

Pass Features:

  • 2 Day conference pass
  • Networking Sessions
  • Lunch and Refreshments
  • Complimentary Articles and Content

Venue

Millennium Gloucester Hotel, 4-18 Harrington Gardens, Kensington, London, SW7 4LH

Europe's second CAR-T Congress will be taking place in Millenium Gloucester Hotel, London.

Situated in stylish Kensington, the 4-star Millennium Gloucester Hotel London is 100 yards from Gloucester Road Tube Station. It offers elegant air-conditioned rooms, a wide array of on-site dining options and a fitness room.

Bedroom rate: £140.00 + vat including breakfast (single occupancy)

Book now: 

T: + 44 (0) 207 331 6195 reseverations direct line or main hotel on +44 (0) 207 373 6030

E: [email protected]

Book by 29 December 2018 and always quote KISA290119 to benefit from this rate.

millenium_hotel.png

Accessibility:

We are committed to making our event accessible for everyone. If you are traveling for the event, Cloud of Goods provides mobility scooter rentals, wheelchair rentals, and other mobility solutions. They will deliver directly to you at the event, your hotel, the airport, or any other place of your choosing. Event attendees will receive a 20% discount when they use the code: RENTGEAR032

Visit: https://www.cloudofgoods.com/ 

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

We need some information to know how best to respond to your request below.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.